115 related articles for article (PubMed ID: 31782995)
1. Asymmetric mutant-enriched polymerase chain reaction and quantitative DNA melting analysis of KRAS mutation in colorectal cancer.
Botezatu IV; Kondratova VN; Shelepov VP; Mazurenko NN; Tsyganova IV; Susova OY; Lichtenstein AV
Anal Biochem; 2020 Feb; 590():113517. PubMed ID: 31782995
[TBL] [Abstract][Full Text] [Related]
2. SLAM-MS: Mutation scanning of stem-loop amplicons with TaqMan probes by quantitative DNA melting analysis.
Kondratova VN; Botezatu IV; Shelepov VP; Lichtenstein AV
Sci Rep; 2020 Mar; 10(1):5476. PubMed ID: 32214156
[TBL] [Abstract][Full Text] [Related]
3. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
Zhang X; Wang Y; Gao N; Wang J
Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565
[TBL] [Abstract][Full Text] [Related]
4. Detection of KRAS codon 12 and 13 mutations by mutant-enriched PCR assay.
Chang YS; Er TK; Lu HC; Yeh KT; Chang JG
Clin Chim Acta; 2014 Sep; 436():169-75. PubMed ID: 24863805
[TBL] [Abstract][Full Text] [Related]
5. [Scanning for KRAS, NRAS, BRAF, and PIK3CA mutations by DNA melting analysis with TaqMan probes].
Botezatu IV; Panchuk IO; Stroganova AM; Senderovich AI; Kondratova VN; Shelepov VP; Lichtenstein AV
Mol Biol (Mosk); 2017; 51(1):50-58. PubMed ID: 28251966
[TBL] [Abstract][Full Text] [Related]
6. Impact of fixation artifacts and threshold selection on high resolution melting analysis for KRAS mutation screening.
Pérez-Báez W; García-Latorre EA; Maldonado-Martínez HA; Coronado-Martínez I; Flores-García L; Taja-Chayeb L
Mol Cell Probes; 2017 Oct; 35():34-43. PubMed ID: 28627450
[TBL] [Abstract][Full Text] [Related]
7. Detection of KRAS Mutations in Plasma DNA Using a fully Automated Rapid Detection System in Colorectal Cancer Patients.
Hosoya K; Matsusaka S; Kashiwada T; Suzuki K; Ureshino N; Sato A; Miki Y; Kitera K; Hirai M; Hatake K; Kimura S; Sueoka-Aragane N
Pathol Oncol Res; 2017 Oct; 23(4):737-744. PubMed ID: 28058585
[TBL] [Abstract][Full Text] [Related]
8. Detection of low-level KRAS mutations using PNA-mediated asymmetric PCR clamping and melting curve analysis with unlabeled probes.
Oh JE; Lim HS; An CH; Jeong EG; Han JY; Lee SH; Yoo NJ
J Mol Diagn; 2010 Jul; 12(4):418-24. PubMed ID: 20413678
[TBL] [Abstract][Full Text] [Related]
9. An improved digital polymerase chain reaction protocol to capture low-copy KRAS mutations in plasma cell-free DNA by resolving 'subsampling' issues.
Ono Y; Sugitani A; Karasaki H; Ogata M; Nozaki R; Sasajima J; Yokochi T; Asahara S; Koizumi K; Ando K; Hironaka K; Daito T; Mizukami Y
Mol Oncol; 2017 Oct; 11(10):1448-1458. PubMed ID: 28691390
[TBL] [Abstract][Full Text] [Related]
10. Detection of
Olmedillas-López S; Lévano-Linares DC; Alexandre CLA; Vega-Clemente L; Sánchez EL; Villagrasa A; Ruíz-Tovar J; García-Arranz M; García-Olmo D
World J Gastroenterol; 2017 Oct; 23(39):7087-7097. PubMed ID: 29093617
[TBL] [Abstract][Full Text] [Related]
11. Analysis of KRAS, NRAS and BRAF mutational profile by combination of in-tube hybridization and universal tag-microarray in tumor tissue and plasma of colorectal cancer patients.
Damin F; Galbiati S; Soriani N; Burgio V; Ronzoni M; Ferrari M; Chiari M
PLoS One; 2018; 13(12):e0207876. PubMed ID: 30562355
[TBL] [Abstract][Full Text] [Related]
12. Utility of KRAS mutation detection using circulating cell-free DNA from patients with colorectal cancer.
Yamada T; Iwai T; Takahashi G; Kan H; Koizumi M; Matsuda A; Shinji S; Yamagishi A; Yokoyama Y; Tatsuguchi A; Kawagoe T; Kitano S; Nakayama M; Matsumoto S; Uchida E
Cancer Sci; 2016 Jul; 107(7):936-43. PubMed ID: 27116474
[TBL] [Abstract][Full Text] [Related]
13. [Comparison of real-time PCR-optimized oligonucleotide probe method and Sanger sequencing for detection of KRAS mutations in colorectal and lung carcinomas].
Qiu T; Ling Y; Chen Z; Shan L; Guo L; Lü N; Ying JM
Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):599-602. PubMed ID: 23157827
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications.
Tsiatis AC; Norris-Kirby A; Rich RG; Hafez MJ; Gocke CD; Eshleman JR; Murphy KM
J Mol Diagn; 2010 Jul; 12(4):425-32. PubMed ID: 20431034
[TBL] [Abstract][Full Text] [Related]
15. Sensitive multiplex detection of KRAS codons 12 and 13 mutations in paraffin-embedded tissue specimens.
Laosinchai-Wolf W; Ye F; Tran V; Yang Z; White R; Bloom K; Choppa P; Labourier E
J Clin Pathol; 2011 Jan; 64(1):30-6. PubMed ID: 21030527
[TBL] [Abstract][Full Text] [Related]
16. Selective capture of plasma cell-free tumor DNA on magnetic beads: a sensitive and versatile tool for liquid biopsy.
Kerachian MA; Azghandi M; Javadmanesh A; Ghaffarzadegan K; Mozaffari-Jovin S
Cell Oncol (Dordr); 2020 Oct; 43(5):949-956. PubMed ID: 32495293
[TBL] [Abstract][Full Text] [Related]
17. Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma.
Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
Int J Cancer; 2014 Nov; 135(9):2215-22. PubMed ID: 24659028
[TBL] [Abstract][Full Text] [Related]
18. Wild‑type blocking pcr coupled with internal competitive amplified fragment improved the detection of rare mutation of KRAS.
Peng J; Wei K; Zhao X; Yang K; Wang H; Zhang Y; Guo M; He J; Wu H; Li Y; Zhao N; Huang Q; Fu W
Mol Med Rep; 2017 Sep; 16(3):2726-2732. PubMed ID: 28677778
[TBL] [Abstract][Full Text] [Related]
19. KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer.
Xu JM; Liu XJ; Ge FJ; Lin L; Wang Y; Sharma MR; Liu ZY; Tommasi S; Paradiso A
J Exp Clin Cancer Res; 2014 Dec; 33(1):104. PubMed ID: 25491325
[TBL] [Abstract][Full Text] [Related]
20. TaqMan probes as blocking agents for enriched PCR amplification and DNA melting analysis of mutant genes.
Botezatu IV; Panchuk IO; Stroganova AM; Senderovich AI; Kondratova VN; Shelepov VP; Lichtenstein AV
Biotechniques; 2017 Feb; 62(2):62-68. PubMed ID: 28193149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
